Exon Skipping Duchenne Therapies Explained

Exon skipping therapies for Duchenne are designed for specific DMD gene mutations. They try to help cells skip over an exon, a segment of genetic instructions, so the remaining code can be read in a way that produces a partly functional dystrophin protein.

Why exons matter

The DMD gene is divided into exons. If a mutation disrupts the reading frame, dystrophin production can fail. Exon skipping uses short synthetic molecules to alter how the RNA message is processed.

This approach is mutation-specific. A therapy aimed at exon 51 does not apply to someone whose mutation requires a different skip.

Which approvals exist in the United States

The FDA granted accelerated approval to eteplirsen for patients with mutations amenable to exon 51 skipping. It later approved golodirsen and viltolarsen for exon 53 skipping, and casimersen for exon 45 skipping. (FDA, eteplirsen approval) (FDA, golodirsen approval) (FDA, viltolarsen approval) (FDA, casimersen approval)

Accelerated approval means a drug can be approved based on a surrogate marker reasonably likely to predict clinical benefit, with further evidence expected. It does not mean the clinical benefit is settled for every patient.

Why the evidence is debated

The central debate is whether increased dystrophin levels translate into meaningful clinical outcomes, and how large that benefit may be. Some families and clinicians see these therapies as meaningful options for eligible patients. Some reviewers have raised concerns about small studies, surrogate endpoints, and uncertainty.

Both can be true: a therapy can be available and still have unresolved evidence questions.

What families can ask

Families may want to ask whether the child’s mutation is amenable to any approved exon skip, what evidence supports the option, what monitoring is required, what the realistic goals are, and how treatment burden fits daily life.

A genetic report is essential for this discussion.

What is still uncertain

Long-term clinical effect remains an important question. Access also differs by country, payer, and regulatory system. No exon-skipping therapy applies to all DMD patients.

For more background, read the dystrophin gene explained and gene therapy for DMD.

Disclaimer: This post is informational and does not constitute medical advice. Decisions about diagnosis or treatment must be made with a qualified care team.